自然阿克西内林A的结构修饰:通过平衡的COX抑制来减少结肠炎的副作用
Zhiran Ju1, Ziyi Shang1, Yonghong Liu2
1Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.
Bioorganic chemistry
|February 18, 2024
概括
一种新型化合物,5e,来自轴内林A,通过抑制循环氧化酶-2 (COX-2) 显示出强大的抗炎作用. 这种化合物有效地减少炎症并保护大肠炎,副作用较少.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 海洋天然产品是抗炎药物候选物的丰富来源.
- 素A是一种合成的循环氧化酶-2 (COX-2) 抑制剂,此前已被确定为有前途的抗炎药物.
- 轴内林A的结构修饰旨在发现具有平衡抑制的新型COX抑制剂,以最大限度地减少不良影响.
研究的目的:
- 开发具有平衡COX-1和COX-2抑制的新型循环氧化酶 (COX) 抑制剂.
- 通过对轴内林A的结构性修改,减轻与传统抗炎药物相关的不良影响.
- 在体外和体内评估合成衍生物的抗炎作用潜力.
主要方法:
- 素A衍生物的合成.
- 在体外评估COX-1和COX-2抑制活性和选择性.
- 通过NF-κB和MAPK信号通路对促炎媒介表达的抗炎作用的评估.
- 在体内测试使用硫酸 (DSS) 诱导的性结肠炎模型.
主要成果:
- 化合物5e表现出最高的COX-2抑制活性 (IC50 = 1.74 μM) 和平衡的COX抑制 (选择性指数 = 16.32).
- 在体外研究表明,5e通过NF-κB信号通路抑制了亲炎性介质.
- 在体内测试表明,5e显著减少了组织学损伤,并防止了DSS诱导的急性结肠炎.
结论:
- 化合物5e是一种强大的COX-2抑制剂,具有平衡的COX抑制.
- 5e在体外和体内表现出显著的抗炎活性,向NF-κB通路.
- 化合物5e显示出作为一种抗炎药物具有减少结肠炎相关不良影响的承诺.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
Drugs for Treatment of Constipation-Predominant IBS
164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K


